Obesity - Pipeline Review, H2 2013

Obesity - Pipeline Review, H2 2013


August 30, 2013
541 Pages - SKU: GMD5105862
License type:
Online Download      US $2,000.00
Site License      US $4,000.00
Global Site License      US $6,000.00


Obesity - Pipeline Review, H2 2013

Obesity - Pipeline Review, H2 2013

SummaryGlobal Markets Direct’s, 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Obesity - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Obesity.
  • A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Obesity.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Additional Information

Companies Mentioned

Boehringer Ingelheim GmbH
Shionogi & Co., Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Athersys, Inc.
GlaxoSmithKline plc
Isis Pharmaceuticals, Inc.
Merck & Co., Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Plexxikon Inc.
BioLineRx, Ltd.
Ipsen S.A.
Chong Kun Dang Pharmaceutical
Glenmark Pharmaceuticals Ltd.
GTx, Inc.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Norgine Limited
Pfizer Inc.
VIVUS, Inc.
Zydus Cadila Healthcare Limited
Genfit
Arrowhead Research Corporation
Ligand Pharmaceuticals Incorporated
Calzada Limited
PROLOR Biotech, Inc.
NeuroSearch A/S
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Unigene Laboratories, Inc.
Theratechnologies Inc.
Bukwang Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Phynova Group Ltd
Orexigen Therapeutics, Inc.
DiaMedica Inc.
NeuroVive Pharmaceutical AB
Digna Biotech, S.L.
Betagenon AB
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Upsher-Smith Laboratories, Inc.
Metabolex, Inc
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Spherix Incorporated
Ocera Therapeutics, Inc.
Aileron Therapeutics, Inc.
AngioChem Inc.
Global Health Ventures Inc.
Zafgen Inc.
Ambrx, Inc.
Braasch Biotech LLC
Zealand Pharma A/S
Indus Biotech Private Limited
Intarcia Therapeutics, Inc.
Thrasos, Inc.
Versartis, Inc.
Kainos Medicine, Inc.
Avaxia Biologics, Inc.
Omeros Corporation
Aegis Therapeutics, LLC
BRIDGE BIORESEARCH PLC
Globeimmune, Inc.
Targacept, Inc.
Molecular Design International, Inc.
N-Gene Research Laboratories, Inc.
PepTcell Limited
Galenea Corp.
Verva Pharmaceuticals Limited
Regulus Therapeutics Inc.
Esperion Therapeutics, Inc.
Domainex Ltd.
Lithera, Inc.
DiscoveryBiomed, Inc.
GlaxoSmithKline Inc.
Motif BioSciences, Inc.
Sirona Biochem Corp
Vicore Pharma AB
Reviva Pharmaceuticals Inc.
PharmaIN Corporation
Rhythm Pharmaceuticals

Country

Global

Sector

Metabolic Disorders

More Drug Discovery reports by Global Markets Direct

Endometrial Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Endometrial Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2014’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.This ...
Age Related Macular Degeneration - Pipeline Review, H1 2014 by Global Markets Direct
Age Related Macular Degeneration - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H1 2014’, provides an overview of the ...
Hypercholesterolemia - Pipeline Review, H1 2014 by Global Markets Direct
Hypercholesterolemia - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H1 2014’, provides an overview of the Hypercholesterolemia’s therapeutic pipeline.This report provides comprehensive ...
Cholera - Pipeline Review, H1 2014 by Global Markets Direct
Cholera - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Cholera - Pipeline Review, H1 2014’, provides an overview of the Cholera’s therapeutic pipeline.This report provides comprehensive ...
See all reports like this >>